Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.57 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.50 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30201341 | 1.00 | IDO1 (0.57) | IDO1GPR84PYCR1TRPV1HTR3E | |
| SCHEMBL11707484 | 0.89 | GPR84 (0.55) | IDO1GPR84PYCR1TRPV1HTR3E | |
| SCHEMBL31731921 | 0.85 | IDO1 (0.61) | IDO1GPR84PYCR1HTR3EHTR3B | |
| SCHEMBL120051 | 0.85 | IDO1 (0.61) | IDO1GPR84PYCR1HTR3EHTR3B | |
| SCHEMBL9905577 | 0.82 | PLA2G7 (0.48) | IDO1GPR84KDR | |
| SCHEMBL27687280 | 0.81 | IDO1 (0.62) | IDO1GPR84PYCR1TRPV1HTR3E | |
| SCHEMBL2600197 | 0.81 | IDO1 (0.57) | IDO1GPR84PYCR1TRPV1HTR3E | |
| SCHEMBL5722021 | 0.81 | TRPV1 (0.58) | IDO1GPR84PYCR1TRPV1HTR3E | |
| SCHEMBL16571434 | 0.81 | IDO1 (0.62) | IDO1GPR84PYCR1TRPV1HTR3E | |
| SCHEMBL10656615 | 0.80 | IDO1 (0.65) | IDO1GPR84PYCR1HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2023028056-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023028056-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| CN-102197038-B | Substituted tricyclic acid derivatives as S1P1 receptor agonists for the treatment of autoimmune and inflammatory disorders | ARENA PHARMACEUTICALS, INC. (US) | 2016-04-20 | — | — | CN | disclosed |
| CN-102197038-A | Substituted tricyclic acid derivatives as S1P1 receptor agonists for the treatment of autoimmune and inflammatory disorders | ARENA PHARM INC | 2011-09-21 | — | — | CN | disclosed |
| CN-101379036-B | Anthranilamide/2-amino-heteroarene carboxamide derivatives | HOFFMANN LA ROCHE | 2011-06-01 | — | — | CN | disclosed |
| CN-1993323-B | Indole, indazole or indoline derivatives | HOFFMANN LA ROCHE | 2011-04-20 | — | — | CN | disclosed |
| CN-101379036-A | Anthranilamide/2-amino-heteroarene carboxamide derivatives | HOFFMANN LA ROCHE (CH) | 2009-03-04 | — | — | CN | disclosed |
| CN-101379022-A | Benzamide and heteroarene derivatives | HOFFMANN LA ROCHE (CH) | 2009-03-04 | — | — | CN | disclosed |
| CN-101220024-A | A set of anti-cancer compound restraining kinase | XIAOMIN DU (CN) | 2008-07-16 | — | — | CN | disclosed |
| CN-1993323-A | Indole, indazole or indoline derivatives | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | CN | disclosed |
| CN-1649820-A | Compounds that modulate PPAR activity and methods for preparing the same | WARNER LAMBERT CO (US) | 2005-08-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | CACNA1E, TRPV1, SCN3A | IDO1 3864/4885GPR84 798/4885PYCR1 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.